In the graft model of melanoma, IL-12 promoted the expression of Tbet in ILC3, leading to the development of “ex-ILC-3s”, which have a phenotypic similarity to ILC-1 and displayed antitumor functions [190]. This evidence concerns the gene TBX21 and melanoma.